These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. Kantarci OH; Lebrun C; Siva A; Keegan MB; Azevedo CJ; Inglese M; Tintoré M; Newton BD; Durand-Dubief F; Amato MP; De Stefano N; Sormani MP; Pelletier D; Okuda DT Ann Neurol; 2016 Feb; 79(2):288-94. PubMed ID: 26599831 [TBL] [Abstract][Full Text] [Related]
4. Prospective study of multiple sclerosis with early onset. Ghezzi A; Pozzilli C; Liguori M; Marrosu MG; Milani N; Milanese C; Simone I; Zaffaroni M Mult Scler; 2002 Apr; 8(2):115-8. PubMed ID: 11990867 [TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis in Pakistan. Wasay M; Ali S; Khatri IA; Hassan A; Asif M; Zakiullah N; Ahmed A; Malik A; Khealani B; Haq A; Fredrikson S Mult Scler; 2007 Jun; 13(5):668-9. PubMed ID: 17548448 [TBL] [Abstract][Full Text] [Related]
6. The prevalence of multiple sclerosis, distribution of clinical forms of the disease and functional status of patients in Csongrád County, Hungary. Bencsik K; Rajda C; Füvesi J; Klivényi P; Járdánházy T; Török M; Vécsei L Eur Neurol; 2001; 46(4):206-9. PubMed ID: 11721128 [TBL] [Abstract][Full Text] [Related]
7. Progression in familial and nonfamilial MS. Koch M; Uyttenboogaart M; Heerings M; Heersema D; Mostert J; De Keyser J Mult Scler; 2008 Apr; 14(3):300-6. PubMed ID: 18208881 [TBL] [Abstract][Full Text] [Related]
9. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy. Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800 [TBL] [Abstract][Full Text] [Related]
10. Predictive value of clinical characteristics for 'benign' multiple sclerosis. Ramsaransing GS; De Keyser J Eur J Neurol; 2007 Aug; 14(8):885-9. PubMed ID: 17662009 [TBL] [Abstract][Full Text] [Related]
11. Identical lesion morphology in primary progressive and relapsing-remitting MS--an ultrahigh field MRI study. Kuchling J; Ramien C; Bozin I; Dörr J; Harms L; Rosche B; Niendorf T; Paul F; Sinnecker T; Wuerfel J Mult Scler; 2014 Dec; 20(14):1866-71. PubMed ID: 24781284 [TBL] [Abstract][Full Text] [Related]
12. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802 [TBL] [Abstract][Full Text] [Related]
13. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Silversides JA; Heggarty SV; McDonnell GV; Hawkins SA; Graham CA Mult Scler; 2004 Apr; 10(2):149-52. PubMed ID: 15124759 [TBL] [Abstract][Full Text] [Related]
14. The natural history of primary progressive multiple sclerosis. Koch M; Kingwell E; Rieckmann P; Tremlett H Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074 [TBL] [Abstract][Full Text] [Related]
15. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Turner B; Lin X; Calmon G; Roberts N; Blumhardt LD Mult Scler; 2003 Feb; 9(1):21-7. PubMed ID: 12617263 [TBL] [Abstract][Full Text] [Related]
16. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311 [TBL] [Abstract][Full Text] [Related]
17. Natural history of multiple sclerosis: a unifying concept. Confavreux C; Vukusic S Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308 [TBL] [Abstract][Full Text] [Related]